Replies to post #2 on Oric Pharmaceuticals Inc (ORIC)

[TheFinalCD]

Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a total of $25 million. The companies plan to move the treatment into a Phase 2 clinical trial in combination with elranatamab, Pfizer's investigational treatment of multiple myeloma

https://finance.yahoo.com/news/oric-pharmaceuticals-announces-clinical-development-224800151.html